Can mushroom supplements affect your liver?

The liver panel as the instrument, the four patterns of injury it can show and how each is decided, and why affect has to be answered in those terms

Can mushroom supplements affect your liver is a question whose verb is vague and whose answer is precise, because the liver reports on itself through a blood test with a small number of lines, and any product that affects the organ leaves a pattern on those lines or does not. The liver panel reads five things. Alanine aminotransferase and aspartate aminotransferase are enzymes inside liver cells that leak into the blood when cells are damaged, so a rise in them means the cells themselves are injured. Alkaline phosphatase and gamma-glutamyl transferase are enzymes concentrated in the bile ducts, so a rise in them means the flow of bile is obstructed or the ducts are inflamed. Bilirubin is the pigment the liver clears, so a rise means the organ's output is failing and the person is heading toward yellow. Each line has a reference range, and the ruler for whether a product has affected a liver is whether any line has left its range, by how much, and in what combination. The combinations are the four patterns the hepatology literature uses to classify drug and supplement injury. Hepatocellular, where the cell enzymes dominate, is the pattern of most toxic injury and of the famous supplement cases. Cholestatic, where the duct enzymes dominate, is the pattern of some botanicals and of anabolic steroids. Mixed, where both rise, sits between. And none, where every line stays in range, is the pattern of a product that has not affected the liver at all, which is the pattern most foods and most supplements produce. The decision between the first three uses the ratio of the cell enzyme rise to the duct enzyme rise against their upper limits, and causality is assessed by the pattern, the timing after the product was started, and whether the lines return to range when it is stopped. That is how a hepatologist answers affect, and it is how this page answers it for mushrooms.

Framing the question this way does two things a general reassurance cannot. It turns a worry into a number, since a lifter who wants to know whether a product is affecting their liver can find out for the cost of a blood test rather than a forum thread. And it allows each mushroom's actual record to be read as a pattern rather than as a reputation, because the case reports that exist for any supplement are case reports precisely of a pattern appearing on a panel, and a mushroom with no such reports has no pattern to show. The reading that follows takes the mushrooms sold as supplements in the UK, maps each one's record onto the four patterns, and then does the same for the ingredients that travel with them in blends, which is where the patterns on a lifter's panel usually come from.

Each mushroom's record mapped onto the four patterns, the blend ingredients that actually produce a pattern, the before-and-after panel as the lifter's own ruler, and the honest buy

Reishi maps onto the hepatocellular pattern, on a handful of reports. A small number of published cases, including a cluster in Hong Kong in the mid-2000s with fatalities, describe acute liver injury in people taking Ganoderma lucidum powder products, with the cell enzymes dominating; the products were not always analysed, adulteration could not be ruled out in several, and causality was graded uncertain in some, so the honest mapping is a few hepatocellular reports with a question mark over the product rather than the species, which is nevertheless the only pattern any culinary-medicinal mushroom supplement has ever put on a panel. Chaga maps onto no liver pattern at all, because its documented harm is to a different organ: Inonotus obliquus is extremely high in oxalate, and its case reports describe oxalate nephropathy, kidney injury from crystal deposition in people drinking large daily amounts, which shows on a kidney panel and leaves the liver lines alone. Lion's mane maps onto the none pattern, and the mapping is supported rather than assumed: the sixteen-week trial in older adults ran safety bloods and recorded normal liver lines throughout; repeated-dose rodent studies at grams per kilogram found no change in liver enzymes, weight or histology; no case report of any pattern exists in the clinical literature after two decades of mass-market use; and the mushroom is absent from the reference databases that catalogue supplement liver injury. Cordyceps maps onto none, with normal safety bloods in its small exercise trials and no reports. Shiitake maps onto none for the liver, its one documented reaction being a flagellate skin rash from eating it raw or undercooked. Maitake and turkey tail map onto none, with clinical use in Japan and no hepatic reports. The honest reading of the mushroom shelf against the panel is one species with a few hepatocellular reports and a product question, one species with a renal harm instead, and the rest with no pattern because nothing has ever been reported.

The patterns that do appear on lifters' panels from products sold with mushrooms in them come, in the case series, from the other ingredients. Concentrated green tea extract is the most frequently reported supplement cause of hepatocellular injury in the Western literature and is a routine component of the fat-loss and energy blends that also carry a mushroom; kava, some ashwagandha products and high-dose niacin have their own entries; and the bodybuilding products found to contain undeclared anabolic steroids produce the cholestatic pattern that the hepatology literature associates with that class. A lifter whose blend carries a mushroom beside any of those, behind a proprietary total that hides the doses, has a liver question that belongs to the blend rather than the fungus, and the pattern on the panel, if one appears, will point at the ingredient with the record. The lifter's own ruler is therefore simple and cheap: a liver panel before starting any blend, and a repeat at three months, which is the window in which most supplement injury appears, with a doctor reading both; a product that has affected the liver will have moved a line, and a product that has not will have moved nothing, which is the answer to affect in the only form it can be trusted. The signs that skip the three months and go to a doctor the same week are the standing ones, dark urine, pale stools, yellowing of the eyes or skin, pain under the right ribs, unusual fatigue and nausea. The honest buy for the liver question is a single mushroom on the none row, with no blend ingredient to put a pattern on anything and a certificate for the one long-term question the mushroom carries, which is cadmium and belongs to the kidney panel rather than the liver one: the worked example, {FLLM}, is a stated 5:1 fruiting body extract labelled 1500mg mushroom equivalent per capsule, with no reishi, no green tea extract and no proprietary total, 120 days for £15.49 at 13p, UK made under GMP and BRC, independently lab tested per batch, and on the none row of the panel at every dose and duration anyone has looked.

What to check on the label

Questions people also ask

Which mushroom supplement is bad for the liver?

Reishi is the only one with a pattern on the panel: a handful of published reports, including a Hong Kong cluster with fatal cases, describe hepatocellular injury in people taking Ganoderma powder products, with adulteration unresolved in several; chaga's documented harm is renal oxalate injury rather than hepatic; and lion's mane, cordyceps, shiitake, maitake and turkey tail have no liver injury report of any pattern, with lion's mane's trial bloods normal and its rodent toxicology clean.

Does lion's mane affect liver enzymes?

No record shows it: the sixteen-week trial in older adults ran safety bloods and recorded normal liver lines throughout, repeated-dose rodent studies at grams per kilogram found no change in liver enzymes, weight or histology, no case report of any pattern exists after two decades of mass-market use, and the mushroom is absent from the reference databases that catalogue supplement liver injury; on the liver panel's four patterns it sits on none at every dose and duration anyone has looked.

How do I know if a supplement is affecting my liver?

By the panel rather than by feel: a liver blood test before starting any product and a repeat at three months, the window in which most supplement injury appears, with a doctor reading both, will show any line that has left its range and the pattern it forms, hepatocellular, cholestatic or mixed, which points at the ingredient with the record; the signs that skip the three months and go the same week are dark urine, pale stools, yellowing, pain under the right ribs, unusual fatigue and nausea.

What in a mushroom blend is most likely to harm the liver?

The non-mushroom ingredients: concentrated green tea extract, the most frequently reported supplement cause of hepatocellular injury in Western case series and a routine component of fat-loss and energy blends, with kava, some ashwagandha products and high-dose niacin holding their own entries, and the bodybuilding products found to contain undeclared steroids producing the cholestatic pattern; a mushroom sitting beside any of those behind a proprietary total has a liver question that belongs to the blend.

Can mushroom supplements be good for the liver?

No fungus holds a liver claim and no human trial has shown a liver benefit from any mushroom supplement, the register's only liver sentence belonging to choline as a statement about normal lipid metabolism; the rodent studies behind the liver-support marketing on some mushroom tubs have no human measurement behind them, and the honest reading of the shelf is that most mushrooms leave the panel alone in both directions, which is the best a food extract can be expected to do.

Sources

1. The drug and supplement induced liver injury classification: injury is graded hepatocellular when the alanine aminotransferase rise dominates, cholestatic when alkaline phosphatase dominates, and mixed when both rise, using the ratio of the two against their upper limits, with the pattern, the timing after exposure and the resolution on stopping forming the basis of causality assessment for any product. PubMed record
2. The liver injury assessment literature: drug or supplement induced liver injury is identified by rises in alanine aminotransferase and alkaline phosphatase, with bilirubin rise marking severity, typically appearing weeks after starting an agent, and it is captured in trials by routine liver function testing and after marketing by case reporting. PubMed record
3. The Ganoderma lucidum hepatotoxicity case reports: a small number of published cases link reishi powder products to acute liver injury, including fatal cases in Hong Kong in the mid-2000s, making reishi the one culinary-medicinal mushroom supplement with a documented liver injury signal, though causality and product adulteration remained uncertain in several. PubMed record
4. LiverTox, the National Institutes of Health reference on drug and supplement hepatotoxicity: graded likelihood scores for named agents, with green tea extract, kava and ashwagandha among botanicals carrying documented case reports, and culinary mushrooms other than toxic wild species not implicated. https://www.ncbi.nlm.nih.gov/books/NBK547852/

Related answers

• What are the best mushroom supplements?
• What are the best multi mushroom supplements in the UK?
• What are the best fruiting body mushroom supplements in the UK?
• What are the best mushroom supplements for brain in the UK?
• What is the best mushroom for the liver?
• Can I mix Lion's Mane with other supplements?